Deucravacitinib Plaque Psoriasis Trial vs. Zasocitinib Completes Primary Phase

A Phase 3 study comparing deucravacitinib with zasocitinib in adults with plaque psoriasis completed its primary data collection on 2026-04-22. This trial, identified as NCT06973291, aims to assess whether zasocitinib works better than deucravacitinib for moderate-to-severe plaque psoriasis.

Background

The study, titled "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis," focuses on individuals living with moderate-to-severe plaque psoriasis. This Phase 3 trial directly compares deucravacitinib and zasocitinib, which are both under investigation for the treatment of plaque psoriasis.

Trial design

The study (NCT06973291) is a Phase 3, randomized trial that enrolled 606 participants with plaque psoriasis. The main objective is to evaluate the comparative efficacy of zasocitinib against deucravacitinib. Participants were assigned to take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo. The treatment period was 16 weeks, with participants remaining in the study for up to 25 weeks, including a screening period and a safety follow-up period.

What this means

The completion of the primary data collection for this Phase 3 trial marks a significant milestone in the evaluation of zasocitinib against deucravacitinib for plaque psoriasis. While specific results regarding efficacy and safety are not yet available, this step indicates progress toward understanding the comparative profiles of these two treatments. The data collected will be crucial for future analyses and potential regulatory submissions, offering insights into treatment options for patients with moderate-to-severe plaque psoriasis.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06973291, titled "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis," was posted on 2026-04-22 on clinicaltrials.gov.